"Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, announced completion of enrollment in NB-301, the largest of its Phase III clinical trials, for Contrave®, its lead obesity product candidate."Obesity is NOT a central nervous system disorder.
It is a condition due to consuming more Calories than are burned.
What is central here, is the attempt of this company to get your money.
"Forward-Looking StatementsCaveat investor.
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements....
All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995."
Posts
No comments:
Post a Comment